The maker of Ozempic and Wegovy obesity drugs said some of the prices could come down, as President Trump called for drugmakers to immediately lower their prices for Medicaid. This comes as Novo ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

Trump demands U.S. drug prices match lowest international rates for some or face executive action. This article originally ...

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

U.S.-listed shares of Novo Nordisk (NVO) rose 0.5% in early premarket trading Wednesday after the Danish drugmaker reported ...

The shrinking ranks of "Dividend Knight" contenders. Healthcare stocks with hard times but high yields. What investors should ...

The Trump administration is launching a pressure campaign against prescription drugmakers in an effort to get them to lower ...

CMS often withholds coverage for reimbursement, disrupting the natural flow of the market and hindering access to proven ...

Weight loss medications such as Wegovy and Zepbound have garnered an enormous amount of attention recently for their ability to help some users lose significant amounts of weight relatively easily.

These tariffs would drastically undermine the price advantage Indian drug makers currently enjoy in the US, especially in ...